PF-2771 is a selective inhibitor of centromere-associated protein E (CENP-E) with potent antitumor activity; it inhibits CENP-E motor activity (IC50 = 16.1 nM) and exhibits cytotoxicity against basal-like breast cancer tumor cell survival (EC50 < 0.1 μM) without significant toxicity toward normal or premalignant cell lines (EC50 > 5 μM); it induces chromosome congression defects in MDA-MB-468 cells and causes tumor regression in SCID mice bearing AA1077 mammary tumors upon daily intraperitoneal administration (100 mg/kg).